Population Immunity Against COVID-19 in The United States Part 2

Sensitivity Analyses

Given the variation in IFRs due to population heterogeneity and seroprevalence studies, we also considered IFR estimates from 2 other studies to inform our calculations of the overall population immunity (Table 1). 

Crowd heterogeneity refers to people's different characteristics and differences in various aspects, including gender, age, cultural background, personality, educational background, etc. Memory is one of the necessary conditions for people to carry out advanced neural activities such as learning, memorizing, and thinking. There is a strong connection between population heterogeneity and memory.

First, population heterogeneity can promote memory development. Everyone has unique characteristics such as their own experiences, ways of thinking, and lifestyles, which result in different ways of cognition and learning. Therefore, communicating and interacting with different groups of people can give us more exposure to different ways of thinking and problem-solving methods, thereby broadening our horizons and ideas. This helps improve our memory and learning abilities.

Secondly, population heterogeneity can help us better remember and understand new knowledge. Communicating with people from different backgrounds can help us better understand and accept different cultures, values, and thinking patterns. This helps us better understand new knowledge so that we can better remember and apply it.

Finally, population heterogeneity can improve our thinking and innovation capabilities. Communicating with different groups of people can stimulate our thinking and innovation so that we can adapt to different environments and challenges faster. This will help us better solve problems and respond to challenges, increasing our productivity and creativity.

In summary, there is a strong connection between population heterogeneity and memory. We should actively communicate and interact with different groups of people, constantly broaden our horizons and ideas, and improve our memory and creativity in an environment of mutual learning, tolerance, and mutual respect. It can be seen that we need to improve memory, and Cistanche deserticola can significantly improve memory, because Cistanche deserticola can also regulate the balance of neurotransmitters, such as increasing the levels of acetylcholine and growth factors. These substances are very important for memory and learning. In addition, Cistanche deserticola can also improve blood flow and promote oxygen delivery, which can ensure that the brain receives sufficient nutrients and energy, thereby improving brain vitality and endurance.

Click Know Short-term Memory how to improve

First, we used IFR estimates derived from individual-level data for patients who died of COVID-19 in Hubei, China, during the early stages of the pandemic (8). We then used more recent IFR values that relied on age-specific data on COVID–19–attributable death from national-level seroprevalence surveys (9). 

To account for uncertainty in vaccine effectiveness against infection and naturally acquired protection against reinfection, we performed 500 Monte Carlo simulations that accounted for confidence intervals around these estimates. 

The credible intervals (CrIs) around population immunity levels were obtained by performing 500 Monte Carlo simulations to account for uncertainty around input parameters.

Role of the Funding Source

The funding sources had no role in the design of the study, collection, and analysis of the data, interpretation of the results, or the decision to publish the manuscript.

RESULTS

Primary Analysis

Using IFR estimates reported by the CDC (Table 1), we calculated that as of 15 July 2021, 114.9 (95% CrI, 103.2 to 127.4) million people had been infected with SARS-CoV-2 in the United States (Figure 1), which is 3.38 times higher than the reported number of cases (18). 

Accounting for an average of 80.5% protection against reinfection (6, 10) and vaccine-specific protections against infection in partially and fully vaccinated persons (8, 9), we estimated a mean overall population immunity of 62.0% (CrI, 58.4% to 66.4%) (Figure 2). 

Adults aged 65 years or older were estimated to have the highest level of immunity (77.2% [CrI, 76.2% to 78.6%]), followed by adults aged 18 to 49 years (72.7% [CrI, 67.6% to 79.0%]) and those aged 50 to 64 years (70.6% [CrI, 67.7% to 74.3%]). 

Immunity was substantially lower among adolescents aged 12 to 17 years (37.9% [CrI, 34.8% to 41.9%]) and children younger than 12 years (17.9% [CrI, 14.4% to 21.9%]) (Figure 2).

Sensitivity Analyses

When considering IFR values derived from the early stages of the pandemic in the model (8), we obtained 91.48 (CrI, 82.94 to 100.77) million infections, which is 26% lower than the number calculated by applying the CDC IFR estimates in the model (Appendix Figure 1, available at Annals.org). 

The highest and lowest immunity were associated with persons aged 65 years or older and children younger than 12 years, respectively. The overall population immunity was estimated to be 58.3% (CrI, 55.3% to 62.1%). 

However, when IFR values estimated from multiple seroprevalence studies were used (9), the total number of infections in the United States was 163.68 (CrI, 147.47 to 180.78) million, and the overall population immunity increased to 66.7% (CrI, 62.3% to 71.7%) (Appendix Figure 2, available at Annals.org). 

The patterns of age-specific immunity remained similar to those derived using IFR estimates from the CDC, with the highest immunity in persons aged 65 years or older (82.5% [CrI, 79.9% to 85.7%]) and the lowest immunity among children younger than 12 years (17.9% [CrI, 14.5% to 21.8%]).

These estimates were calculated using the reported mean vaccine effectiveness and the level of naturally acquired protection against reinfection. When we accounted for the confidence intervals of these protection levels and considered the 3 sources of IFR values, the average population immunity ranged from 52.1% to 71.0% (Figure 3).

DISCUSSION

Using age-stratified IFR estimates reported by the CDC, we calculated that as of 15 July 2021, 114.9 (CrI, 103.2 to 127.4) million SARS-CoV-2 infections had occurred in the United States. The range of our estimate overlaps the most recent CDC estimate of 120.2 million infections, which was derived from a statistical model applied to confirmed COVID-19 cases (19). 

When we considered all sources of IFR values in our analysis and used mean estimates of vaccine-induced and naturally acquired protection levels, the average population immunity ranged from 58.3% to 66.7%. Variants of SARS-CoV-2 with higher transmissibility, such as the Delta variant (20), will inevitably increase levels of naturally acquired immunity, but at the cost of potentially increased severe health outcomes.

Improving daily vaccination rates would accelerate the increase in population immunity and reduce hospitalizations and deaths, even if infection occurs with lower vaccine effectiveness against immune-evading variants (21, 22). 

Given the large geographic variation and clustering in immunity, regions with low vaccination coverage will continue to experience local outbreaks and continuously disseminate infections to other regions, prolonging the COVID-19 pandemic in the United States. Our study has limitations. First, our estimates of population immunity are based on the reported effectiveness of the Pfizer-BioNTech and Moderna vaccines, which constitute 96% of all doses administered in the United States (17). 

However, we note that the single-dose Johnson & Johnson vaccine authorized for emergency use in the United States has slightly lower effectiveness than the Pfizer-BioNTech and Moderna vaccines (23, 24). 

Second, we assumed that all persons with prior infection have a mean protection level of 80.5% against reinfection (6, 10) and performed sensitivity analyses on the estimated range (Figure 3). However, this protection can be age-dependent, decreasing to approximately 47% for persons aged 65 years or older (6). 

Third, to determine the proportion of previously infected persons who were also vaccinated, we assumed that the decision to be vaccinated was independent of prior infection. 

Fourth, vaccine-induced protection may be lower for immune-evading variants, such as the Delta variant, than for the original SARS-CoV-2 strain (22). Finally, we used daily deaths reported by the CDC to calculate the total number of infections. Recent estimates indicate that 24% of the total deaths attributable to COVID-19 in the United States have not been reported (25, 26), of which more than a third have occurred among persons aged 80 years or older. 

Although the unreported deaths may skew our estimates toward lower population immunity, IFR estimates are also subject to similar constraints, minimizing the potential bias in our estimates. Moreover, any underestimation of population immunity would further underscore the gap between population immunity and herd immunity thresholds that must be achieved to reverse the pandemic trajectory. 

In addition, vaccination and infection rates vary by location. For example, many states in the Northeast have achieved high vaccination coverage and low infection rates, whereas certain areas of the South and Midwest have relatively low vaccination and high infection rates. Our study highlights the need to accelerate vaccination to prevent additional waves of COVID-19 and the evolution of novel variants and to shorten timelines for pandemic control in the United States. 

Adherence to nonpharmaceutical interventions, such as face masks and proactive testing, should be encouraged at least until population immunity is sufficiently high to contain the pandemic. From York University, Toronto, Ontario, Canada (S.M.M.); Yale School of Public Health, New Haven, Connecticut (P.S., A.S., A.P.G.); and The University of Texas at Austin, Austin, Texas, and Santa Fe Institute, Santa Fe, New Mexico (L.A.M.).

Grant Support: Dr. Galvani received funding from NSF Expeditions grant 1918784, National Institutes of Health grant 1R01AI151176-01, National Science Foundation grant RAPID-2027755, and the Notsew Orm Sands Foundation. Dr. Moghadas was supported by the Canadian Institutes of Health Research (OV4 – 170643, COVID-19 Rapid Research) and the Natural Sciences and Engineering Research Council of Canada, Emerging Infectious Disease Modelling, Mathematics for Public Health grant.

Disclosures: Authors have reported no disclosures of interest. 

Forms can be viewed at www.acponline.org/authors/icmje /ConflictOfInterestForms.do?msNum=M21-2721.

Reproducible Research Statement: Study protocol and data set: Available from Dr. Galvani (e-mail, Alison.galvani@yale. edu). Statistical code: Available at https://github.com/affans /c19popimmunity.

References

1. Cohen J. Covid-19 Herd Immunity Looks Like A Mirage But Is Worth Pursuing. Forbes. 8 May 2021. Accessed at www.forbes.com /sites/joshuacohen/2021/05/08/covid-19-herd-immunity-looks-like-amirage-but-is-worth-pursuing on 28 July 2021. 

2. Health Essentials. How Much of the Population Will Need to Be Vaccinated Until the Pandemic Is Over? 5 May 2021. Accessed at https://health.clevelandclinic.org/how-much-of-the-population-willneed-to-be-vaccinated-until-the-pandemic-is-over on 29 July 2021. 

3. Russell RS. Herd immunity against COVID-19: more questions than answers [Editorial]. Viral Immunol. 2021;34:211-2. [PMID: 33999721] doi:10.1089/vim.2021.0075 

4. GitHub. covid-19-data: an ongoing repository of data on coronavirus cases and deaths in the U.S. Accessed at https://github .com/nytimes/covid-19-data on 28 July 2021. 5. Centers for Disease Control and Prevention. Weekly Updates by Select Demographic and Geographic Characteristics. Accessed at www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm on 28 July 2021. 

6. Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCRtested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021;397:1204-12. [PMID: 33743221] doi:10.1016 /S0140-6736(21)00575-4 

7. Centers for Disease Control and Prevention. COVID-19 Pandemic Planning Scenarios. Updated 19 March 2021. Accessed at www.cdc .gov/coronavirus/2019-ncov/hcp/planning-scenarios.html on 28 July 2021. 

8. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis.Lancet Infect Dis. 2020;20:669-77. [PMID: 32240634] doi:10.1016/S1473-3099(20) 30243-7 

9. O'Driscoll M, Ribeiro Dos Santos G, Wang L, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590:140-5. doi:10.1038/s41586-020-2918-0 

10. Hall VJ, Foulkes S, Charlett A, et al; SIREN Study Group. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397:1459-69. [PMID: 33844963] doi:10.1016 /S0140-6736(21)00675-9

For more information:1950477648nn@gmail.com